Calcifediol (25-Hydroxyvitamin D3) in the Treatment of Uremic Bone Disease
Authors: STEVEN L. TEITELBAUM
Journal: Annals of Internal Medicine (1981)

Editorial Notes1 March 1981Calcifediol (25-Hydroxyvitamin D3) in the Treatment of Uremic Bone DiseaseSTEVEN L. TEITELBAUM, M.D.STEVEN L. TEITELBAUM, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-3-404 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptRenal osteodystrophy is a generic term referring to the many morphologic and biochemical abnormalities of the skeleton in uremia. Although various combinations exist, the basic histologic features of the disorder are those of osteitis fibrosa (which reflects hyperparathyroidism) and osteomalacia (or defective mineralization).Within the past two decades, a great deal of information has accumulated on the pathogenesis of uremic bone disease (1). For example, the severity of the secondary hyperparathyroidism accompanying renal failure is clearly related to various factors, not the least of which are hyperphosphatemia and hypocalcemia. Consequently, therapy has been directed toward controlling blood phosphorus levels by...References1. AVIOLITEITELBAUM LS. Renal osteodystrophy. In: EARLEY LE, GOTTSCHALK CW, eds. Strauss and Welt's Diseases of the Kidney. 3rd ed. Boston: Little, Brown and Co.; 1979:307-70. Google Scholar2. AVIOLIBIRGELEESLATOPOLSKY LSSE. The metabolic fate of vitamin D3-3H in chronic renal failure. J Clin Invest. 1966;47:2239-52. CrossrefGoogle Scholar3. POTTERWILSONOZONOFF DCM. Hyperparathyroid bone disease in children undergoing long-term hemodialysis; treatment with vitamin D. J Pediatr. 1974;85:60-6. CrossrefMedlineGoogle Scholar4. TEITELBAUMHRUSKASHIEBERDEBNAMNICHOLS SKWJS. Tetracycline fluorescence in uremic and primary hyperparathyroid bone. Kidney Int. 1977;12:366-72. CrossrefMedlineGoogle Scholar5. EISMANHAMSTRAKREAMDELUCA JABH. 1,25-dihydroxyvitamin D in biological fluids: a simplified and sensitive assay. Science. 1976;193:1021-3. CrossrefMedlineGoogle Scholar6. BRICKMANCOBURNNORMAN AJA. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man. N Engl J Med. 1972;287;891-5. CrossrefMedlineGoogle Scholar7. RECKERSCHOENFELDLETTERISLATOPOLSKYGOLDSMITHBRICKMAN RPJERA. The efficacy of calcifediol in renal osteodystrophy. Arch Intern Med. 1978;138:857-63. CrossrefMedlineGoogle Scholar8. TEITELBAUMBONESTEIN SJP. Calcifediol in chronic renal insufficiency: skeletal response. JAMA. 1976;235:164-7. CrossrefMedlineGoogle Scholar9. FROSTGRIFFITHJEEKIMMELMCCANDLISTEITELBAUM HDWDRS. Histomorphometric changes in trabecular bone of renal failure patients treated with calcifediol. Metab Bone Dis Related Res. In press. Google Scholar10. BORDIERZINGRAFFGUERIS PJJ. The effect of 1α(OH)D3 and 1α,25(OH)2D3 on the bone in patients with renal osteodystrophy. Am J Med. 1978;64:101-7. CrossrefMedlineGoogle Scholar11. PIERIDESELLISSIMPSONDEWARWARDKERR AHWJMD. Variable response to long-term 1α-hydroxycholecalciferol in haemodialysis osteodystrophy. Lancet. 1976;1:1092-5. CrossrefMedlineGoogle Scholar12. RUTHERFORDBORDIERMARIE WPP. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest. 1977;60:332-41. CrossrefMedlineGoogle Scholar13. TEITELBAUMBERGFELDFREITAGHRUSKASLATOPOLSKY SMJKE. Do parathyroid hormone and 1,25-dihydroxyvitamin D modulate bone formation in uremia? J Clin Endocrinol Metab. 1980;51:247-51. CrossrefMedlineGoogle Scholar14. ELLISMCCARTHYHERRINGTON HJJ. Bone aluminum in haemodialyzed patients and in rats injected with aluminum chloride: relationship to impaired bone mineralisation. J Clin Pathol. 1979;32:832-44. CrossrefMedlineGoogle Scholar15. HEALYMALLUCHEGOLDSTEINSINGERMASSRY MHDFS. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med. 1980;140:1030-3. CrossrefMedlineGoogle Scholar16. HOLICKDE BLANCOCLARK MMM. The metabolism of [6-3H]1α, 25-dihydroxycholecaliferol to [6-3H]1α, 25-dihydroxycholecalciferol in a patient with renal insufficiency. J Clin Endocrinol Metab. 1977;44:595-8. CrossrefMedlineGoogle Scholar17. HADDADROJANASATHIT JS. Acute administration of 25-hydroxycholecalciferol in man. J Clin Endocrinol Metab. 1976;42:284-90. CrossrefMedlineGoogle Scholar18. CHRISTIANSENRøDBROCHRISTENSENHARTNACKTRANSBøL CPMBI. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet. 1978;2:700-3. CrossrefMedlineGoogle Scholar19. TOUGAARDSøRENSENBRøCHNER-MORTENSENCHRISTENSENRøDBROSøRENSEN LEJMPA. Controlled trial of 1α-hydroxycholecalcalciferol in chronic renal failure. Lancet. 1976;1:1044-7. CrossrefMedlineGoogle Scholar20. MASSRYGOLDSTEIN SD. Is calcitriol [1,25(OH)2D3] harmful to renal function? JAMA. 1979;242:1875-6. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Division of Bone and Mineral Metabolism and Department of Pathology and Laboratory Medicine The Jewish Hospital of St. Louis Washington University School of Medicine St. Louis, Missouri PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByManagement of chronic renal failure in childrenReview: Renal Osteodystrophy—Pathogenesis TreatmentRenal Osteodystrophy—Pathogenesis and TreatmentCalcium regulation 1 March 1981Volume 94, Issue 3Page: 404-405KeywordsBloodBoneHyperparathyroidismHypocalcemiaPathogenesisPhosphorusRenal diseasesRenal failureSkeleton Issue Published: 1 March 1981 PDF DownloadLoading ...